UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down

Diabetologia, 2011, Vol.54 (1), p.10-18

2011

Volltextzugriff (PDF)

comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study

Diabetologia, 2007-02, Vol.50 (2), p.259-267

2007

Volltextzugriff (PDF)

Polypharmacy in people with Type 1 and Type 2 diabetes is justified by current guidelines-a comprehensive assessment of drug prescriptions in patients needing inpatient treatment for diabetes-associated problems

Diabetic medicine, 2014-09, Vol.31 (9), p.1078-1085

2014

Volltextzugriff (PDF)

Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans

Diabetologia, 2006-03, Vol.49 (3), p.452-458

2006

Volltextzugriff (PDF)

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

International journal of clinical practice (Esher), 2009-01, Vol.63 (1), p.46-55

2009

Volltextzugriff (PDF)

Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation?

Diabetologia, 2013-09, Vol.56 (9), p.1878-1883

2013

Volltextzugriff (PDF)

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial

Diabetes, obesity & metabolism, 2007-03, Vol.9 (2), p.194-205

2007

Volltextzugriff (PDF)

Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia

Diabetologia, 2003-06, Vol.46 (6), p.798-801

2003

Volltextzugriff (PDF)

Glucagon-like peptide 1 (GLP-1)

Molecular metabolism (Germany), 2019-12, Vol.30, p.72-130

2019

Volltextzugriff (PDF)

Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes

Experimental and clinical endocrinology & diabetes, 2006-09, Vol.114 (8), p.417-423

2006

Volltextzugriff (PDF)

The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1

Diabetologia, 2005-04, Vol.48 (4), p.608-611

2005

Volltextzugriff (PDF)

Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?

British heart journal, 2004-01, Vol.90 (1), p.9-12

2004

Volltextzugriff (PDF)

Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study

Diabetes, obesity & metabolism, 2015-09, Vol.17 (9), p.849-858

2015

Volltextzugriff (PDF)

Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects

Diabetes (New York, N.Y.), 1995-09, Vol.44 (9), p.1126-1131

1995

Volltextzugriff (PDF)

Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects

Diabetologia, 2007-04, Vol.50 (4), p.806-813

2007

Volltextzugriff (PDF)

Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes

Diabetologia, 2005-09, Vol.48 (9), p.1872-1881

2005

Volltextzugriff (PDF)

Glucagon-like Peptide 1 (GLP-1) in the Treatment of Diabetes

Hormone and metabolic research, 2004-11, Vol.36 (11/12), p.852-858

Nauck, M. A.

2004

Volltextzugriff (PDF)

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients

Diabetologia, 1993-08, Vol.36 (8), p.741-744

1993

Volltextzugriff (PDF)

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients

Diabetes care, 1996-06, Vol.19 (6), p.580-586

1996

Volltextzugriff (PDF)

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

Diabetes, obesity & metabolism, 2009-12, Vol.11 (12), p.1163-1172

2009

Volltextzugriff (PDF)

enteroinsular axis may mediate the diabetogenic effects of TCF7L2 polymorphisms

Diabetologia, 2007-12, Vol.50 (12), p.2413-2416

2007

Volltextzugriff (PDF)

α-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients

Diabetic medicine, 2005-04, Vol.22 (4), p.470-476

2005

Volltextzugriff (PDF)

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM

Diabetologia, 1996-12, Vol.39 (12), p.1546-1553

1996

Volltextzugriff (PDF)

Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations

The journal of clinical endocrinology and metabolism, 1993-04, Vol.76 (4), p.912-917

1993

Volltextzugriff (PDF)

Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial

Diabetes, obesity & metabolism, 2015-11, Vol.17 (11), p.1056-1064

2015

Volltextzugriff (PDF)

1 – 25 von 821

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(703)
Mit Volltextzugriff
(608)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(463)
Humans
(440)
Life Sciences & Biomedicine
(434)
Male
(277)
Female
(237)
Middle Aged
(206)
Biological And Medical Sciences
(204)
Adult
(184)
Endocrinology & Metabolism
(177)
Medical Sciences
(172)
Aged
(142)
Diabetes
(82)
Diabetes Mellitus, Type 2 - Drug Therapy
(78)
Blood Glucose - Metabolism
(77)
Endocrinopathies
(69)
Fundamental And Applied Biological Sciences. Psychology
(66)
Glucagon-Like Peptide 1
(65)
Insulin - Blood
(62)
Risk Factors
(61)
Endocrine Pancreas. Apud Cells
(60)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down

comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study

Polypharmacy in people with Type 1 and Type 2 diabetes is justified by current guidelines-a comprehensive assessment of drug prescriptions in patients needing inpatient treatment for diabetes-associated problems

Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation?

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial

Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia

Glucagon-like peptide 1 (GLP-1)

Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes

The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1

Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?

Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study

Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects

Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects

Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes

Glucagon-like Peptide 1 (GLP-1) in the Treatment of Diabetes

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

enteroinsular axis may mediate the diabetogenic effects of TCF7L2 polymorphisms

α-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM

Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations

Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial

Suchergebnisse filtern